US 505(b)(2) Regulatory Pathway and Strategies
US 505(b)(2) Regulatory Pathway and Strategies
US 505(b)(2) Regulatory Pathway and Strategies
- No tags were found...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Differentiated Products Now Essentially DriveEconomics of <strong>US</strong> Generics: MylanDuragesicEpiPenPaxil CRDitropan XLPlendilLevothyroxineBystolicRoyaltiesSularBase* EPSTotal EPS (%)Percent incremental contribution to 2008 cash EPS (%)1042 2 1 9Differentiatedproductscontributed**~92% of „08cash EPS271610029*Base EPS includes commodity generics, O-<strong>US</strong> generics, Matrix**Incremental contributionReference: Ronny Gal, Research Analyst, Sanford C. Bernstein & Co. Presentation atGPhA 2009 Annual Meeting
Change language